March 29, 2022, New York — Insilico Medicine, an end-to-end artificial intelligence (AI)-focused drug discovery company, today announced that it has created a unique approach to identify potential drug targets with dual use for aging and age-associated diseases with PandaOmics, its proprietary AI-based biological target discovery platform. Research supporting this approach has been published in Aging (March 2022).
People all over the world are living longer. According to the World Health Organization (WHO), one in six people worldwide will be 60 or older by 2030. However, aging increases vulnerability to a wide range of human disorders, including cancers, diabetes , cardiovascular diseases and neurodegenerative diseases. . About two-thirds of the 150,000 people who die every day worldwide suffer from age-related diseases.
Recent research on aging suggests that targeting the aging process itself could improve many age-related pathologies. The proposed research by Insilico Medicine scientists aims to use AI to identify potential targets that are implicated in multiple age-associated diseases and also play a role in the fundamental biology of aging. The results of this research may have substantial benefits for the discovery and development of therapies for aging and age-related diseases.
Insilico Medicine used its PandaOmics platform to perform target identification for 14 age-associated diseases (AADs) and 19 non-age-associated diseases (NAADs) across multiple disease domains to identify associated disease targets at the age. In a comprehensive assessment, 145 genes were considered potential aging-related targets and mapped into corresponding aging characteristics, including 69 high-confidence targets with high potential pharmacogability, 48 medium novel targets with high pharmacogability medium to high potential, and 28 very novel targets with medium potential pharmacogability.
“The development of interventions that target multiple age-associated diseases and aging itself could lead to unprecedented health benefits, not only by treating diseases, but also by extending lifespan and providing new candidates for drug reuse,” said Alex Zhavoronkov PhD, CEO of Insilico Medicine. “The current study also demonstrated the power of the PandaOmics AI-powered target discovery platform to identify novel dual-use targets not only for specific disorders, but for multiple disease types, enabling biologists and clinicians to further investigate their therapeutic potential in a cost- and time-saving way. »
A list of potential dual-use aging therapeutic targets for drug discovery has been disclosed in the article.
The paper is available here: https://www.aging-us.com/article/203960/text
PandaOmics enables systems biology research on multiple data types, including multi-omics and textual data, and deploys AI-powered analytical capabilities to facilitate the rapid discovery of new targets or the prioritization of established targets against existing ones. diseases of interest. PandaOmics can serve as a business intelligence tool at the target identification stage of drug discovery to optimize portfolio development with strategies that can maximize novelty and trust.
About Insilico Medicine
Insilico Medicine, an end-to-end clinical-stage artificial intelligence (AI)-focused drug discovery company, connects clinical trial biology, chemistry and analytics using novel AI systems. generation. The company has developed AI platforms that use deep generative models, reinforcement learning, transformers and other modern machine learning techniques to discover new targets and design new molecular structures with desired properties. Insilico Medicine offers breakthrough solutions to discover and develop innovative drugs against cancer, fibrosis, immunity, central nervous system (CNS) diseases and age-related diseases.
For more information, visit www.insilico.com.
For media inquiries, please contact firstname.lastname@example.org.
The title of the article
Aging-based dual-purpose disease characteristics and age-associated targets are predicted using PandaOmics’ AI-powered discovery engine
Warning: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.